Study guide

15.3 Acid-Base Disorders & Blood Gas Analysis

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

15.3 Acid-Base Disorders & Blood Gas Analysis

Key Takeaways Explain This Topic AI

Systematic arterial blood gas (ABG) interpretation follows 5 steps: evaluating pH (acidaemia <7.35, alkalaemia >7.45), identifying the primary disturbance, assessing physiological compensation, calculating the serum anion gap, and performing delta-delta gap analysis.

In metabolic acidosis, respiratory compensation is predicted by Winter's formula: expected PaCO2 (mmHg) = 1.5 × [HCO3-] + 8 ± 2; an actual PaCO2 higher than predicted indicates concurrent respiratory acidosis, whereas a lower PaCO2 indicates concurrent respiratory alkalosis.

High anion gap metabolic acidosis (HAGMA; AG >14 mmol/L) is caused by unmeasured fixed acid anions recalled by GOLD MARK (Glycols, Oxoproline/paracetamol, L-lactate, D-lactate, Methanol, Aspirin, Renal failure, Ketoacidosis); the Delta-Delta ratio (ΔAG / Δ[HCO3-]) identifies mixed disorders (<0.4–0.8 indicates concurrent NAGMA, >1.5–2.0 indicates concurrent metabolic alkalosis).

Normal anion gap metabolic acidosis (NAGMA / hyperchloraemic) is differentiated using the urine anion gap (UAG = [Na+] + [K+] - [Cl-]): negative UAG (<0) indicates appropriate renal ammonium excretion in GI bicarbonate loss (diarrhoea), whereas positive UAG (>0) confirms defective distal renal acid excretion (Type 1 distal RTA).

Metabolic alkalosis is classified by urinary chloride: saline-responsive (urinary chloride <20 mmol/L; vomiting, NG suction, past diuretics) which resolves with 0.9% saline rehydration, versus saline-resistant (urinary chloride >20 mmol/L; primary aldosteronism, Conn's, Cushing's, severe hypokalaemia, Bartter/Gitelman) which requires targeted therapy.

Last updated: September 2026

Systemic acid-base homeostasis maintains arterial pH strictly between 7.35 and 7.45 ([H+] = 35–45 nmol/L). The primary extracellular buffer is the bicarbonate-carbonic acid system, governed by the Henderson-Hasselbalch relationship:

pH = 6.1 + log([HCO3-] / (0.03 × PaCO2 [mmHg]))

Arterial blood gas (ABG) analysis is a core competency for MRCP(UK) Part 1. Mastering systematic step-by-step interpretation, compensation rules, anion gap, delta gap, and urinary electrolytes ensures diagnostic precision.

  • 1. Systematic 5-Step ABG Interpretation Protocol 5-STEP ABG PROTOCOL
  • │
  • ┌────────────────────────┼────────────────────────┐
  • ▼ ▼ ▼
  • STEP 1: pH / [H+] STEP 2: Primary Process STEP 3: Compensation
  • <7.35 = Acidaemia • Low HCO3 = Met Acid • Winter's Formula
  • >7.45 = Alkalaemia • High PaCO2 = Resp Acid • Resp Acid/Alk Rules
  • 7.35-7.45 = Normal/ • High HCO3 = Met Alk (Never overcompensates)
  • Mixed Disorder • Low PaCO2 = Resp Alk
  • │
  • ┌────────────────────────┴────────────────────────┐
  • ▼ ▼
  • STEP 4: Anion Gap STEP 5: Delta-Delta Ratio
  • AG = Na - (Cl + HCO3) • Delta AG / Delta HCO3
  • Normal: 10-14 mmol/L • <0.4-0.8 = Mixed HAGMA + NAGMA
  • Correct for Albumin! • >1.5-2.0 = Mixed HAGMA + Met Alk
  • Step 1: Examine the pH and [H+]

pH < 7.35 ([H+] > 45 nmol/L): Acidaemia .

pH > 7.45 ([H+] < 35 nmol/L): Alkalaemia .

Normal pH (7.35–7.45): Either completely normal physiology OR a balanced, complex mixed acid-base disorder (e.g. concurrent severe metabolic acidosis and metabolic alkalosis).

Step 2: Determine the Primary Process

Identify the parameter whose change direction matches the pH:

In acidaemia: reduced [HCO3-] (<22 mmol/L) defines a metabolic acidosis ; elevated PaCO2 (>6.0 kPa / >45 mmHg) defines a respiratory acidosis .

In alkalaemia: elevated [HCO3-] (>26 mmol/L) defines a metabolic alkalosis ; reduced PaCO2 (<4.7 kPa / <35 mmHg) defines a respiratory alkalosis .

Step 3: Assess Physiological Compensation

Physiological compensation never overcompensates; it brings the pH towards, but never across, the 7.40 neutral mark. If measured compensation deviates from expected values, a secondary independent acid-base disorder is present:

Metabolic Acidosis Compensation (Winter's Formula): Expected PaCO2 (mmHg) = 1.5 × [HCO3-] + 8 ± 2 (In SI units: Expected PaCO2 (kPa) = [1.5 × [HCO3-] + 8 ± 2] / 7.5).

If measured PaCO2 > expected: Concurrent respiratory acidosis (e.g. DKA with central respiratory depression, exhaustion, or underlying COPD).

If measured PaCO2 < expected: Concurrent respiratory alkalosis (e.g. sepsis, salicylate toxicity, pulmonary embolism).

Metabolic Alkalosis Compensation: Expected PaCO2 (mmHg) = 0.7 × [HCO3-] + 20 ± 5 (PaCO2 rises via compensatory hypoventilation, but rarely exceeds 55–60 mmHg / 7.3–8.0 kPa due to hypoxaemic respiratory drive).

Acute vs. Chronic Respiratory Acidosis:

Acute: For every 10 mmHg (1.33 kPa) acute rise in PaCO2, [HCO3-] rises by 1 mmol/L (cellular buffering).

Chronic (>48h): For every 10 mmHg (1.33 kPa) chronic rise in PaCO2, [HCO3-] rises by 3.5–4 mmol/L (renal H+ secretion and bicarbonate generation).

Acute vs. Chronic Respiratory Alkalosis:

Acute: For every 10 mmHg (1.33 kPa) acute fall in PaCO2, [HCO3-] falls by 2 mmol/L .

Chronic: For every 10 mmHg (1.33 kPa) chronic fall in PaCO2, [HCO3-] falls by 4–5 mmol/L .

  • Step 4: Calculate the Serum Anion Gap (AG)
  • Serum Anion Gap = [Na+] - ([Cl-] + [HCO3-])

Normal reference range: 10–14 mmol/L (unmeasured anions like albumin, phosphate, and sulfate exceed unmeasured cations like calcium and magnesium).

Albumin Correction: Serum albumin accounts for ~75% of the normal anion gap. For every 10 g/L reduction in serum albumin below 40 g/L, the baseline normal AG drops by 2.5 mmol/L : Corrected AG = Observed AG + 0.25 × (40 - Serum Albumin [g/L]) (In hypoalbuminaemic critically ill patients, failure to correct the anion gap masks a severe high anion gap acidosis).

Step 5: Delta Gap / Delta-Delta Analysis

In High Anion Gap Metabolic Acidosis (HAGMA), delta analysis detects occult coexisting metabolic disorders:

  • ΔAG = Observed AG - 12
  • Δ[HCO3-] = 24 - Observed [HCO3-]
  • Delta-Delta Ratio = ΔAG / Δ[HCO3-]

Ratio 0.8–1.2: Pure uncomplicated HAGMA (one molecule of organic acid consumes exactly one molecule of bicarbonate).

Ratio <0.4–0.8: Δ[HCO3-] is disproportionately greater than ΔAG. Bicarbonate is lower than predicted. Confirms a concurrent Normal Anion Gap (Hyperchloraemic) Metabolic Acidosis (e.g. DKA with severe diarrhoea, or DKA resuscitated with excessive 0.9% saline).

Ratio >1.5–2.0: ΔAG is disproportionately greater than Δ[HCO3-]. Bicarbonate is higher than predicted. Confirms a concurrent Metabolic Alkalosis (e.g. DKA or alcoholic ketoacidosis complicated by severe vomiting) or pre-existing compensated chronic hypercapnia.

2. High Anion Gap Metabolic Acidosis (HAGMA): The GOLD MARK Mnemonic

HAGMA (>14 mmol/L) is generated by the accumulation of unmeasured organic or inorganic fixed acids:

G — Glycols (Ethylene Glycol, Propylene Glycol): Ethylene glycol (antifreeze) is metabolized by alcohol dehydrogenase to glycolate and oxalate, causing severe HAGMA, high osmolar gap, acute kidney injury with calcium oxalate monohydrate envelope- or needle-shaped crystals in urine, and cranial neuropathies. Treatment: Fomepizole or IV ethanol, and urgent haemodialysis.

O — 5-Oxoproline (Pyroglutamic Acid): Occurs in malnourished, elderly females taking chronic therapeutic paracetamol (acetaminophen) in the setting of critical illness or hepatic/renal impairment. Glutathione depletion uncouples the gamma-glutamyl cycle, producing massive 5-oxoproline accumulation. Treatment: Discontinue paracetamol; administer intravenous N-acetylcysteine.

L — L-Lactate:

Type A (Tissue Hypoperfusion / Hypoxia): Septic shock, cardiogenic shock, hypovolaemia, mesenteric ischaemia, carbon monoxide poisoning, severe asphyxia.

Type B (Cellular / Toxin / Metabolic): Metformin toxicity (especially with acute renal impairment), severe liver failure, haematological malignancy (Warburg effect), phaeochromocytoma, propofol infusion syndrome, linezolid, and thiamine deficiency (wet beriberi).

D — D-Lactate: Produced by intestinal bacterial fermentation of unabsorbed carbohydrates in patients with short bowel syndrome , jejunoileal bypass, or severe malabsorption. Standard laboratory lactate assays detect only L-lactate and are entirely negative. Presents with episodic HAGMA, ataxia, slurred speech, confusion, and encephalopathy.

M — Methanol: Ingestion of methylated spirits or adulterated alcohol. Metabolized by alcohol dehydrogenase to formic acid . Produces severe HAGMA, elevated osmolar gap, visual loss with optic disc hyperaemia ('snowstorm vision') , and bilateral basal ganglia (putaminal) necrosis. Treatment: Fomepizole or ethanol, intravenous folinic acid, and emergent haemodialysis.

A — Aspirin / Salicylates: In overdose, salicylates uncouple oxidative phosphorylation, driving accumulation of pyruvic, lactic, and keto acids. Classically presents as a mixed disorder: primary respiratory alkalosis (direct stimulation of the medullary respiratory center) combined with primary HAGMA . Treatment: Urinary alkalinisation with intravenous 8.4% sodium bicarbonate, dextrose, and urgent haemodialysis if salicylate >700 mg/L (>5 mmol/L) or severe neurotoxicity.

R — Renal Failure / Uraemia: Advanced AKI or CKD (eGFR <15–20 mL/min). Decreased glomerular filtration and tubular excretion of inorganic sulfates, phosphates, and urate.

K — Ketoacidosis:

Diabetic Ketoacidosis (DKA): Insulin deficiency driving lipolysis and ketogenesis (β-hydroxybutyrate and acetoacetate).

Alcoholic Ketoacidosis (AKA): Chronic alcoholism with recent heavy binging followed by abrupt cessation and vomiting/starvation. Characterized by profound ketonaemia with normal or low blood glucose.

Starvation Ketoacidosis: Mild ketonaemia after prolonged fasting; bicarbonate rarely drops below 16–18 mmol/L.

3. Normal Anion Gap Metabolic Acidosis (NAGMA) & Urine Anion Gap

In NAGMA, the loss of bicarbonate is matched by an equimolar retention of chloride by the kidneys to preserve electroneutrality, resulting in hyperchloraemic metabolic acidosis with a normal anion gap (10–14 mmol/L).

  • Feature High Anion Gap Metabolic Acidosis (HAGMA) Normal Anion Gap Metabolic Acidosis (NAGMA)
  • Serum Anion Gap Elevated (>14 mmol/L, often >20–30) Normal (10–14 mmol/L)
  • Serum Chloride Normal Elevated (Hyperchloraemia, typically >108–112 mmol/L)

Primary Mechanism Addition of unmeasured fixed acids (A-); H+ titrates HCO3-, leaving A- unmeasured Direct physical loss of HCO3- or failure of renal H+ excretion with compensatory renal Cl- retention

Etiologies GOLD MARK (Glycols, Oxoproline, L-lactate, D-lactate, Methanol, Aspirin, Renal failure, Ketoacidosis) Gastrointestinal losses (diarrhoea, enterostomy, fistula), Renal Tubular Acidosis (Types 1, 2, 4), Acetazolamide, Iatrogenic 0.9% saline resuscitation

Urine Anion Gap (UAG) Not applicable Critical discriminator: Differentiates GI bicarbonate loss (negative UAG) from Distal RTA (positive UAG)

  • The Urine Anion Gap (UAG)
  • Urine Anion Gap (UAG) = [Urine Na+] + [Urine K+] - [Urine Cl-]

The healthy kidney excretes excess fixed acid primarily in the form of ammonium (NH4+) paired with chloride (NH4Cl). Because ammonium is an unmeasured cation, high renal excretion of NH4Cl causes urinary chloride to substantially exceed the sum of urinary sodium and potassium.

Negative UAG (<0, typically -20 to -50 mmol/L): Indicates intact renal ammoniagenesis and distal hydrogen ion secretion. Diagnoses: Gastrointestinal bicarbonate loss (severe diarrhoea, laxative abuse, enterocutaneous fistula).

Positive UAG (>0, typically +10 to +40 mmol/L): Indicates impaired distal renal ammonium excretion. Diagnoses: Type 1 (Distal) Renal Tubular Acidosis .

Summary of Renal Tubular Acidosis (RTA)

Type 1 (Distal RTA): Inability of collecting duct α-intercalated cells to secrete H+ via H+-ATPase. Urine pH persistently >5.5 despite severe systemic acidaemia , positive UAG, hypokalaemia, hypercalciuria, hypocitraturia, and recurrent medullary nephrocalcinosis. Associated with autoimmune diseases (Sjögren's, SLE), amphotericin B, and lithium. Treatment: Oral sodium bicarbonate or potassium citrate.

Type 2 (Proximal RTA): Defective proximal tubular bicarbonate reabsorption. Variable urine pH (<5.5 once serum bicarbonate falls below the reduced tubular threshold). Hypokalaemia, absence of nephrocalcinosis. Frequently associated with generalized proximal dysfunction ( Fanconi syndrome : renal glycosuria with normal blood sugar, aminoaciduria, phosphaturia with rickets/osteomalacia). Associated with multiple myeloma, Wilson's disease, and tenofovir. Treatment: High-dose oral bicarbonate.

Type 4 (Hyperkalaemic RTA): Aldosterone deficiency or resistance. Decreased aldosterone reduces ENaC activity, impairing luminal electronegativity and blunting both K+ and H+ secretion. Hyperkalaemia , hyperchloraemic metabolic acidosis, urine pH <5.5. Causes: Diabetic nephropathy (hyporeninaemic hypoaldosteronism), Addison's disease, ACE inhibitors, ARBs, spironolactone, amiloride, trimethoprim, calcineurin inhibitors. Treatment: Fludrocortisone, loop diuretics, potassium restriction.

4. Metabolic Alkalosis: Saline-Responsive vs Saline-Resistant

Metabolic alkalosis (arterial pH > 7.45, [HCO3-] > 26 mmol/L) is classified by measuring spot urinary chloride , which guides definitive therapy: Metabolic Alkalosis

  • (pH > 7.45, HCO3 > 26)
  • │
  • Measure Spot Urinary Chloride
  • ┌───────────────┴───────────────┐
  • ▼ ▼
  • Urinary Chloride <20 Urinary Chloride >20
  • SALINE-RESPONSIVE SALINE-RESISTANT
  • │ │
  • Vomiting / NG suction • Primary Hyperaldosteronism
  • Prior diuretic therapy (Conn's Syndrome)
  • Volume/Chloride depletion • Cushing's Syndrome
  • Paradoxical aciduria • Severe hypokalaemia (<2.0)
  • │ • Bartter / Gitelman
  • RESUSPENSION WITH 0.9% NaCl │
  • DOES NOT RESPOND TO SALINE
  • (Treat underlying endocrinopathy)
  • Saline-Responsive Metabolic Alkalosis (Urinary Chloride <20 mmol/L)

Etiology: Prolonged vomiting, nasogastric suction, prior loop or thiazide diuretic therapy (after diuretic effect has waned), villous adenoma of the rectum, congenital chloridorrhoea.

Pathophysiology: Loss of gastric HCl produces volume contraction, hypochloraemia, and hypokalaemia. Hypochloraemia limits chloride delivery to the cortical collecting duct, impairing apical pendrin (Cl- / HCO3- exchanger) activity, preventing bicarbonate excretion. Concurrent hypovolaemia stimulates aldosterone, which drives Na+ reabsorption and forces intercalated cells to excrete H+ and K+ into urine, generating paradoxical aciduria .

Management: Rapidly corrects with intravenous 0.9% Sodium Chloride and potassium chloride supplementation. Saline expands intravascular volume (suppressing aldosterone) and replenishes chloride, permitting pendrin to excrete bicarbonate.

Saline-Resistant Metabolic Alkalosis (Urinary Chloride >20 mmol/L)

Etiology: Primary aldosteronism (Conn's syndrome, bilateral adrenal hyperplasia), Cushing's syndrome, renovascular hypertension, excessive licorice ingestion (glycyrrhizic acid), renin-secreting tumors, Liddle syndrome, Bartter syndrome, Gitelman syndrome, and profound hypokalaemia ([K+] < 2.0 mmol/L).

Pathophysiology: Autonomous mineralocorticoid activity drives continuous ENaC sodium reabsorption, lumen-negative voltage, and intercalated cell H+-ATPase secretion, independent of volume or chloride status.

Management: Does NOT correct with 0.9% saline. Requires specific therapy directed at the underlying endocrinopathy (unilateral adrenalectomy in Conn's adenoma, spironolactone/eplerenone in bilateral hyperplasia, amiloride in Liddle syndrome).

5. Respiratory Acidosis vs. Respiratory Alkalosis

Respiratory Acidosis (PaCO2 > 6.0 kPa / >45 mmHg):

Acute: Uncompensated or minimally compensated ([HCO3-] rises 1 mmol/L per 10 mmHg PaCO2 rise). Central respiratory depression (opioid overdose, benzodiazepine toxicity, severe stroke), acute airway obstruction, cardiac arrest, flail chest, acute neuromuscular failure (myasthenia gravis crisis, Guillain-Barré syndrome).

Chronic: Fully compensated ([HCO3-] rises 3.5–4 mmol/L per 10 mmHg PaCO2 rise). Severe COPD, obesity hypoventilation syndrome (Pickwickian syndrome), severe kyphoscoliosis, motor neurone disease (ALS).

Respiratory Alkalosis (PaCO2 < 4.7 kPa / <35 mmHg):

Acute: Minimal compensation ([HCO3-] falls 2 mmol/L per 10 mmHg PaCO2 drop). Psychogenic hyperventilation / panic attack, acute pulmonary embolism (tachypnoea and hypoxaemia), early salicylate toxicity, acute asthma (prior to exhaustion), high altitude.

Chronic: Fully compensated ([HCO3-] falls 4–5 mmol/L per 10 mmHg PaCO2 drop). Chronic liver failure / hepatic cirrhosis, pregnancy (progesterone-mediated respiratory stimulation), prolonged mechanical hyperventilation.